Effects of anti-IL-5 monoclonal antibody on the murine model of nasal allergy

被引：19
|
作者：
Asakura, K [1 ]
Saito, H [1 ]
Watanabe, M [1 ]
Ogasawara, H [1 ]
Matsui, T [1 ]
Kataura, A [1 ]
机构：
[1] Sapporo Med Univ, Dept Otolaryngol, Chuo Ku, Sapporo, Hokkaido 060, Japan
来源：
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY | 1998年 / 116卷 / 01期
关键词：
nasal allergy; anti-IL-5 monoclonal antibody; murine model;
D O I：
10.1159/000023924
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
IL-5 is known to be closely related to the infiltration, activation and proliferation of eosinophils. In this study, we evaluated the in vivo effects of anti-IL-5 monoclonal antibody (mAb) in the murine model of nasal allergy. The mAb treatment inhibited the antigen-induced late phase eosinophilia, but had no effects on the number of basophilic cells. It also inhibited early phase nasal symptoms, and tended to inhibit histamine hypersensitivity. These findings suggest that IL-5 plays an important role in the pathogenesis of allergic nasal disorders.
引用
收藏
页码：49 / 52
页数：4
相关论文
共 50 条
  • [41] Anti-IL-5 in pediatric allergic diseases
    Tenero, Laura
    Arturi, Elisa
    Piazza, Michele
    Piacentini, Giorgio
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2020, 31 : 14 - 16
  • [42] CRSwNP: Anti-IL-5 Therapy as a Gamechanger
    Fessler, Beate
    ALLERGO JOURNAL, 2022, 31 (01) : 52 - 52
  • [43] Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects?
    Granda, Paula
    Villamanan, Elena
    Carpio, Carlos
    Laorden, Daniel
    Quirce, Santiago
    alvarez-Sala, Rodolfo
    JOURNAL OF ASTHMA, 2024, 61 (08) : 857 - 866
  • [44] ANTI-IL-5 MONOCLONAL-ANTIBODY INHIBITS ALLERGIC LATE PHASE BRONCHIAL EOSINOPHILIA IN GUINEA-PIGS - A THERAPEUTIC APPROACH
    CHAND, N
    HARRISON, JE
    ROONEY, S
    PILLAR, J
    JAKUBICKI, R
    NOLAN, K
    DIAMANTIS, W
    SOFIA, RD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 211 (01) : 121 - 123
  • [45] Anti-IL-4R versus anti-IL-5/5R after anti-IL-5/5R failure in asthma: An emulated target trial
    Valery, Solene
    Simon-Tillaux, Noemie
    Devouassoux, Gilles
    Bonniaud, Philippe
    Beurnier, Antoine
    Boudjemaa, Amel
    Chenivesse, Cecile
    Bourdin, Arnaud
    Gauquelin, Lisa
    Guillo, Sylvie
    Taille, Camille
    Estellat, Candice
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 154 (04) : 922 - 932
  • [46] Severe asthma: anti-IgE or anti-IL-5?
    Papathanassiou, Evgenia
    Loukides, Stelios
    Bakakos, Petros
    EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2016, 3
  • [47] Effects of anti-IL-5 receptor alpha in an ex vivo 3D model of COPD
    Benfante, Alida
    Pitruzzella, Alessandro
    Fucarino, Alberto
    Bucchieri, Fabio
    Scichilone, Nicola
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [48] Inhibitory effects of anti-IL-1β antibody in murine AA amyloidosis model
    Murata, S.
    Ueda, M.
    Tanabe, Y.
    Kurata, N.
    Demura, N.
    Gram, H.
    Tasaki, M.
    Su, Y.
    Jono, H.
    Shono, M.
    Obayashi, K.
    Ando, Y.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2011, 18 : 38 - 39
  • [49] Anti-IL-5 immunomodulates the effect of Staphylococcus aureus enterotoxin on T cell response in nasal polyps
    Langier, S.
    Landsberg, R.
    Sade, K.
    Kivity, S.
    RHINOLOGY, 2011, 49 (05) : 570 - 576
  • [50] Is there a Role for Anti-IL-5 Therapies in Eosinophilic Fascitis?
    Angelopoulos, Andreas
    Kouverianos, Ioannis
    Daoussis, Dimitrios
    MEDITERRANEAN JOURNAL OF RHEUMATOLOGY, 2023, 34 (04):
12345